It should be discussed whether to alter the rules for Her2/neu assessment in GC as it has recently be done for breast cancer 23, where cases with a strong staining and less than 10% positive tumor ratio are newly assigned to ISH testing to reduce the false-negative rate. This evidence concerns the gene ERBB2 and neoplasm.